Table Info

Table 1.

Relevant targetable aberrations in BTCs

Molecular alteration	Incidence (%)	Anatomical location	Investigated agents
FGFR2 gene fusions	14–23	iCCA	Pemigatinib Infigratinib Futibatinib Derazantinib Debio 1347 Erdafitinib
IDH mutations	7–20 (IDH1) 3 (IDH2)	iCCA	Ivosidenib Enasidenib Dasatinib FT-2102
HER2 overexpression/amplification	15	GBC, eCCA	Trastuzumab Trastuzumab-pertuzumab Trastuzumab deruxtecan T-DM1 Zanidatamab
HER2 mutations	1–2	GBC, eCCA, iCCA	Neratinib
HER2 mutations	7	AVC	Neratinib
BRAF V600E mutation	< 5	iCCA	Dabrafenib-trametinib
NTRK fusions	3.5	iCCA	Larotrectinib Entrectinib
MSI-H	1	eCCA, iCCA, GBC	Pembrolizumab

T-DM1: trastuzumab-emtansine; FT-2102: olutasidenib

Declarations

Author contributions

MGP, LR, AC, AD and VZ contributed to conception and design of the work. All authors wrote the manuscript, contributed to manuscript revision, read and approved this submitted version.

Conflicts of interest

LR received consulting fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, BMS, Celgene, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi, Servier, Zymeworks; lecture fees from AbbVie, Amgen, Bayer, Eisai, Gilead, Incyte, Ipsen, Lilly, Merck Serono, Roche, Sanofi; travel expenses from Ipsen; and institutional research funding from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Zymeworks. The other authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. The Lancet. 2021;397:428–44. [DOI]

Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C, et al. Biliary tract cancers: molecular heterogeneity and new treatment options. Cancers (Basel). 2020;12:3370. [DOI]

Ebata T, Ercolani G, Alvaro D, Ribero D, Di Tommaso L, Valle JW. Current status on cholangiocarcinoma and gallbladder cancer. Liver Cancer. 2016;6:59–65. [DOI] [PubMed] [PMC]

Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39 Suppl 1:19–31. [DOI] [PubMed]

Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104–14. [DOI] [PubMed]

Vogel A, Saborowski A. Current and future systemic therapies in biliary tract cancer. Visc Med. 2021;37:32–8. [DOI] [PubMed] [PMC]

Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–89. [DOI] [PubMed]

Marin JJG, Prete MG, Lamarca A, Tavolari S, Landa-Magdalena A, Brandi G, et al. Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer. 2020;123:1047–59. [DOI] [PubMed] [PMC]

Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10:751–65. [DOI] [PubMed] [PMC]

10.

Rimassa L, Personeni N, Aghemo A, Lleo A. The immune milieu of cholangiocarcinoma: from molecular pathogenesis to precision medicine. J Autoimmun. 2019;100:17–26. [DOI] [PubMed]

11.

Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9:1064–79. [DOI] [PubMed] [PMC]

12.

Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, et al. DaBRAFenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (roar): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21:1234–43. [DOI] [PubMed]

13.

Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7:943–62. [DOI] [PubMed] [PMC]

14.

Harding JJ, Cleary JM, Quinn DI, Braña I, Moreno V, Borad MJ, et al. Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: results from the phase II SUMMIT ‘basket’ trial. J Clin Oncol. 2021;39:320. [DOI]

15.

Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122:3838–47. [DOI] [PubMed]

16.

Eso Y, Shimizu T, Takeda H, Takai A, Marusawa H. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol. 2020;55:15–26. [DOI] [PubMed] [PMC]

17.

Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144:829–40. [DOI] [PubMed] [PMC]

18.

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81. [DOI] [PubMed]

19.

Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469–74. [DOI] [PubMed] [PMC]

20.

Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25:391–8. [DOI] [PubMed]

21.

Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30:1950–8. [DOI] [PubMed]

22.

Sakai D, Kanai M, Kobayashi S, Eguchi H, Baba H, Seo S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncology. 2018;29:viii205–70. [DOI]

23.

Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5:824–30. [DOI] [PubMed] [PMC]

24.

Ulusakarya A, Karaboué A, Ciacio O, Pittau G, Haydar M, Biondani P, et al. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer. 2020;20:515. [DOI] [PubMed] [PMC]

25.

Rauthan A, Patil P. Modified FOLFIRINOX regimen in advanced biliary tract adenocarcinoma. J Clin Oncol. 2017;35:484. [DOI]

26.

Phelip JM, Edeline J, Blanc JF, Barbier E, Michel P, Bourgeois V, et al. Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: study protocol for a randomized controlled multicenter phase II/III study. Dig Liver Dis. 2019;51:318–20. [DOI] [PubMed]

27.

McNamara MG, Bridgewater J, Palmer DH, Faluyi O, Wasan H, Patel A, et al. A phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08). Oncologist. 2021;26:e669–78. [DOI] [PubMed] [PMC]

28.

Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690–701. [DOI] [PubMed] [PMC]

29.

Belkouz A, de Vos-Geelen J, Mathôt RAA, Eskens FALM, van Gulik TM, van Oijen MGH, et al. Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. Br J Cancer. 2020;122:634–9. [DOI] [PubMed] [PMC]

30.

Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73:170–85. [DOI] [PubMed]

31.

Walter D, Hartmann S, Waidmann O. Update on cholangiocarcinoma: potential impact of genomic studies on clinical management. Z Gastroenterol. 2017;55:575–81. [DOI] [PubMed]

32.

Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24:4154–61. [DOI] [PubMed] [PMC]

33.

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, et al. Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer. 2017;87:122–30. [DOI] [PubMed]

34.

Graham RP, Fritcher EG, Pestova E, Schulz J, Sitailo LA, Vasmatzis G, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45:1630–8. [DOI] [PubMed]

35.

Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, et al. Identification of a new fibroblast growth factor receptor, FGFR5. Gene. 2001;271:171–82. [DOI] [PubMed]

36.

Hollebecque A, Silverman I, Owens S, Féliz L, Lihou C, Zhen H, et al. Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2⁺) cholangiocarcinoma (CCA) treated with pemigatinib in the FIGHT-202 trial. Ann Oncol. 2019;30:v276. [DOI]

37.

Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;18:2780–94. [DOI] [PubMed] [PMC]

38.

Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671–84. [DOI] [PubMed] [PMC]

39.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. [DOI] [PubMed]

40.

Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, et al. FIGHT-302: first-line pemigatinib vs. gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020;16:2385–99. [DOI] [PubMed]

41.

Javle M, Kelley RK, Roychowdhury S, Weiss KH, Abou-Alfa GK, Macarulla T, et al. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions. HepatoBiliary Surg Nutr. 2019;8:AB051.

42.

Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6:803–15. [DOI] [PubMed]

43.

Makawita S, K Abou-Alfa G, Roychowdhury S, Sadeghi S, Borbath I, Goyal L, et al. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. 2020;16:2375–84. [DOI] [PubMed]

44.

Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, et al. Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80:4986–97. [DOI] [PubMed]

45.

Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. FOENIX-CCA2: a phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. J Clin Oncol. 2020;38:108. [DOI]

46.

Furuse J, Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, et al. Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2. Ann Oncol. 2020;31:S1287–318. [DOI]

47.

Tran B, Meric-Bernstam F, Arkenau H, Bahleda R, Kelley RK, Hierro C, et al. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Ann Oncol. 2018;29:ix46–66. [DOI]

48.

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120:165–71. [DOI] [PubMed] [PMC]

49.

Droz Dit Busset M, Braun S, El-Rayes B, Harris WP, Damjanov N, Masi G, et al. Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications. Ann Oncol. 2019;30:v276–7. [DOI]

50.

Javle MM, Shahib WL, Braun S, Engelhardt M, Borad MJ, Abou-Alfa GK, et al. FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M/A). J Clin Oncol. 2020;38:TPS597. [DOI]

51.

Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer (iCCA) [Internet]. United States & Canada: GlobeNewswire; c2021 [cited 2021 May 5]. Available from: https://www.globenewswire.com/news-release/2021/02/10/2172794/0/en/Basilea-reports-positive-topline-results-from-phase-2-study-FIDES-01-for-derazantinib-in-FGFR2-gene-fusion-positive-patients-with-bile-duct-cancer-iCCA.html

52.

Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation-or amplification-positive patients with bile duct cancer (iCCA) [Internet]. United States & Canada: GlobeNewswire; c2021 [cited 2021 May 5]. Available from: https://www.globenewswire.com/news-release/2021/03/24/2198217/0/en/Basilea-reports-positive-interim-results-from-phase-2-study-FIDES-01-for-derazantinib-in-FGFR2-gene-mutation-or-amplification-positive-patients-with-bile-duct-cancer-iCCA.html

53.

Droz Dit Busset M, Shaib WL, Harris WP, Damjanov N, Borad M, Vogel A, et al. Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: pooled analysis of clinical trials and early access programs. Ann Oncol. 2020;31:S1217–39. [DOI]

54.

Cleary JM, Iyer G, Oh DY, Mellinghoff IK, Goyal L, Ng MCH, et al. Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1347 in patients with solid tumors harboring an FGFR gene fusion. J Clin Oncol. 2020;38:3603. [DOI]

55.

Hyman DM, Goyal L, Grivas P, Meric-Bernstam F, Tabernero J, Hu Y, et al. FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology. J Clin Oncol. 2019;37:TPS3157. [DOI]

56.

Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, et al. Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther. 2017;16:1010–20. [DOI] [PubMed]

57.

Park JO, Feng YH, Chen YY, Su WC, Oh DY, Shen L, et al. Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. J Clin Oncol. 2019;37:4117. [DOI]

58.

Bibeau K, Féliz L, Barrett S, Na L, Lihou CF, Asatiani E. Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: an exploration of response to systemic therapy. J Clin Oncol. 2020;38:588. [DOI]

59.

Abou-Alfa GK, Bibeau K, Schultz N, Yaqubie A, Millanget BM, Ren H, et al. Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma. J Clin Oncol. 2021;39:303. [DOI]

60.

Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med. 2010;16:387–97. [DOI] [PubMed]

61.

Lee K, Song YS, Shin Y, Wen X, Kim Y, Cho NY, et al. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features. Sci Rep. 2020;10:15820. [DOI] [PubMed] [PMC]

62.

Lowery MA, Abou-Alfa GK, Burris HA, Janku F, Shroff RT, Cleary JM, et al. Phase 1 study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts. J Clin Oncol. 2017;35:4015.

63.

Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796–807. [DOI] [PubMed] [PMC]

64.

Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. J Clin Oncol. 2021;39:266. [DOI]

65.

Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016;138:881–90. [DOI] [PubMed] [PMC]

66.

Lowery MA, Bradley M, Chou JF, Capanu M, Gerst S, Harding JJ, et al. Binimetinib plus gemcitabine and cisplatin phase I/II trial in patients with advanced biliary cancers. Clin Cancer Res. 2019;25:937–45. [DOI] [PubMed] [PMC]

67.

Doherty M, Tam VC, McNamara MG, Hedley DW, Dhani NC, Chen EX, et al. Selumetinib (sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): a randomized trial. J Clin Oncol. 2018;36:4084. [DOI]

68.

Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, et al. Pan-cancer efficacy of vemurafenib in BRAFV600-mutant non-melanoma cancers. Cancer Discov. 2020;10:657–63. [DOI] [PubMed] [PMC]

69.

Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–36. [DOI] [PubMed] [PMC]

70.

Yarlagadda B, Kamatham V, Ritter A, Shahjehan F, Kasi PM. Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma. NPJ Precis Onc. 2019;3:19. [DOI]

71.

Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22:1290–300. [DOI] [PubMed]

72.

Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, et al. Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. J Clin Oncol. 2020;38:TPS4654. [DOI]

73.

Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee JJ, et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer. 2019;125:902–9. [DOI] [PubMed] [PMC]

74.

Kim RD, Sanoff HK, Poklepovic AS, Soares H, Kim J, Lyu J, et al. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer. 2020;126:3464–70. [DOI] [PubMed] [PMC]

75.

Demols A, Borbath I, Van den Eynde M, Houbiers G, Peeters M, Marechal R, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Ann Oncol. 2020;31:1169–77. [DOI] [PubMed]

76.

Assenat E, Portales F, Ychou M. A multicenter phase Ib-IIR trial assessing activity of regorafenib in combination with modified gemcitabine-oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer (aBTC). J Clin Oncol. 2018;36:427. [DOI]

77.

Yeh CN, Chang YC, Su Y, Shin-Shian Hsu D, Cheng CT, Wu RC, et al. Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. Oncotarget. 2017;8:113444–59. [DOI] [PubMed] [PMC]

78.

Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19:235–42 [DOI] [PubMed] [PMC]

79.

Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21:531–40. [DOI] [PubMed] [PMC]

80.

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21:271–82. [DOI] [PubMed] [PMC]

81.

Seesaha PK, Wang KX, Wang GQ, Cui TY, Zhao FJ, Pan LL, et al. Current progress and future perspectives of immune checkpoint inhibitors in biliary tract cancer. Onco Targets Ther. 2021;14:1873–82. [DOI] [PubMed] [PMC]

82.

Bang YJ, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. J Clin Oncol. 2019;37:4079. [DOI]

83.

Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147:2190–8. [DOI] [PubMed]

84.

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10. [DOI] [PubMed] [PMC]

85.

Silva VW, Askan G, Daniel TD, Lowery M, Klimstra DS, Abou-Alfa GK, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin Oncol. 2016;5:62. [DOI] [PubMed]

86.

Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017:PO.17.00073. [DOI] [PubMed] [PMC]

87.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13. [DOI] [PubMed] [PMC]

88.

Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cance. JAMA Oncol. 2020;6:888–94. [DOI] [PubMed] [PMC]

89.

Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4:611–21. [DOI] [PubMed]

90.

Fujiwara Y, Iguchi H, Yamamoto N, Hayama M, Nii M, Ueda S, et al. Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors. Cancer Sci. 2019;110:1715–23. [DOI] [PubMed] [PMC]

91.

Ioka T, Ueno M, Oh DY, Fujiwara Y, Chen JS, Dokiet Y, et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J Clin Oncol. 2019;37:387. [DOI]

92.

Oh DY, Lee KH, Lee DW, Kim TY, Bang JH, Nam AR, et al. Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naive advanced biliary tract cancer (aBTC). J Clin Oncol. 2020;38:4520. [DOI]

93.

Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). Oncologist. 2018;23:1407–e136. [DOI] [PubMed] [PMC]

94.

Villanueva L, Lwin Z, Chung HC, Gomez-Roca C, Longo F, Yanez E, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. J Clin Oncol. 2021;39:321. [DOI]

95.

Chen X, Wu X, Wu H, Shao Q, Zhu F, Qian X, et al. SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: results from a single-arm exploratory study. J Clin Oncol. 2019;37:4092. [DOI]

96.

Ofoeyeno N, Ekpenyong E, Braconi C. Pathogenetic role and clinical implications of regulatory RNAs in biliary tract cancer. Cancers (Basel). 2020;13:12. [DOI]